


AMIS/AMIS Plus

A testimonial to the changes in the management of patients with acute myocardial infarction (AMI) in Switzerland

Franz Eberli, MD Cardiology Stadtspital Zürich, Triemli

1997 – the birth of AMIS






February 1997 Dolly, the first clone of an adult mammal is presented.
Produced by British developmental biologist Ian Wilmut and colleagues of the Roslin Institute in Scotland.



November 1997
Cindy Grines, MD, female
interventional cardiologist, gives
key-note lecture at AHA
advocating primary PCI in STEMI provoking criticism from
established male cardiologists.

Acute Myocardial Infarction Thrombolysis vs. Primary Angioplasty: Short-Term Results

Weaver WD et al. JAMA 1997;278:1876



Meta-Analysis

- -N=2606 patients
- -10 randomized trials
- -1985-1996
- -4x:streptokinase vs PTCA
- -3x: tPA (4hr) vs PTCA
- -3x: acc. tPA vs PTCA

P<0.008

Background on which medical services must be provided



Medical-ethical self-perception

 The wish and the obligation to provide the best possible, patientcentered therapy.

Medical and scientific progression


- Large randomized clinical trials (RCT) enable evidence-based medicine.
- RCT are the base of guidelines.

Technical advancement

- Fast development of new techniques
 - Diagnostic tools (imaging, biomarkers etc.)
 - Information technology
 - New devices, materials, implants (e.g. stents)
- Development of new drugs

AMIS Plus Project






\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			Questionnaire .2009	4	M Myocardial I Infarction in S Switzerland	
Please do not fill out – for internal use only	Incoming mail/Check	Init.	Entry	Init.	P-Code	
AMIS DATA ENTRY IDENTIFICATION						
Hospital		[
Patient ID number		[
VO Set Nr./Code		[
Physician ID/ Date of data entry		_	Date:			
PATIENT AT ADMISSION						
Date of birth			Day Month Year Month			


Weight (eg.: 68.5 kg is rounded up to 0 6 9 kg)

○ Female

1. Cumulative number of the ACS patients enrolled in AMIS Plus (n=33'092)



2. Trends in reperfusion therapy in ST-elevation myocardial infarction patients in Switzerland between 1997 and 2009 (n=18'637)




Reciprocal Effect of Guidelines, Trials and Registries









Aims of AMIS Plus



Collect data and trends on:

- Epidemiology (including risk factors) of patients with acute coronary syndrome
- Diagnostic and therapeutic interventions during hospitalisation
- Compliance with guidelines
- Quality of treatment and outcome during hospitalisation and one year after discharge
- Integration of new diagnostic and therapeutic interventions

...in order to optimise the care of patients with acute coronary syndrome.

Phases of AMIS



- 1. Early Phase (1997-2006)
 - Establishment of primary PCI, optimal drug treatment
- 2. Consolidation Phase (2007-2016)
 - Optimization in the whole of Switzerland
 - Quality control
- 3. New challenges and horizons (2017-)
 - Broadening and differentiation of
 - Etiology of ACS
 - Quality in treatment




AMIS/AMIS Plus Early Phase (1997-2006)

Establishment of primary PCI Optimal drug treatment


First Things First! Establishment of Primary PCI as STEMI Treatment in Switzerland






Impact of RCT on Treatment: Thienopyridines at Discharge






Impact of RCT on Treatment: Start of Statins During Hospital Stay





Lack of Awareness for Symptoms of Myocardial Infarction






HELP Initiative of Swiss Society of Cardiology and Neurology: Goal: Increase Knowledge of myocardial infarction and stroke symptoms

Reduced Gap in Patient Delay between Women and Men with STEMI





Foster-Witassek F et al. Eur Heart J Prev Cardiol 2023




AMIS/AMIS Plus

Consolidation Phase 2007-2016

Trends in immediate drug therapy in STEMI patients (N=31'065)






P2Y12 – ticlopidine, clopidogrel, prasugrel or ticagrelor ACE = angiotensin-converting enzyme inhibitor AT = angiotensin receptor antagonist

2008: Switzerland is Top in Primary PCI in Europe




Number of STEMI Patients Treated with Primary PCI

European STEMI Registry Widimsky P et al. Eur Heart J 2010;31:943-57



Reperfusion therapy in STEMI patients (N=31'283)





Importance of Quality of Process of Care for Primary PCI



- As Process-of-care quality indicator the door-toballoon time (D2B) is established.
- Guidelines
- ESC and AHA/ACC:
 - PCI preferred treatment if performed by an experienced team <90 min after first medical contact (Class 1,

Door-to-Balloon Time Process-of-Care Indicator




- D2B Time
 - Excellent Process-of-care indicator
 - Optimized patient pathway
 - Patient pathway analysis step-by-step possible
 - Targeted improvements possible
 - Very complex indicator, including many additional factors
 - System indicator:
 - Network characteristics
 - Organization of emergency medical services
 - Quality of care givers (emergency medical service, emergency room, doctors, quality of interventional cardiologist)

Disease Management AMI Inselspital Bern 1997



Initiative of Cardiology Department and VISANA Health Insurance

- Participants: Cardiology, ER, ICU, Controlling, Billing, Health Insurance
- Full time fellow: Gabriela Kuster, MD (Fabian Noti: doctoral thesis)



Qualitiy Improvement Initiatives



Door-to-balloon Alliance (ACC 2008):


(JACC Cardiovasc Interv 2008;1:97-104)

PCI <90 min in 75% or more of patients

Prerequisite for timely reperfusion of STEMI by PCI is a well funtioning STEMI network




Evolving changes in the emergency chain for the treatment of myocardial infarction



Switzerland fulfills the goals of the D2B Initiative




Door-to-balloon time <90 min (STEMI patients + PCI)



Crude in-hospital mortality of ACS patients (n=55'627)





reduced by 5% per year (OR 0.95; 95%CI 0.94-0.96; P<0.001)

Lara Gut





Man kann gut sein, aber man kann sich immer verbessern»: Lara Gut. (Lake Louise, 7. 12. 2014)

Even if you are Gut, you always can become better!!



AMIS/AMIS Plus New challenges and horizons (2017-)

Broadening and differentiation of

Etiology of ACS


Quality of treatment


MINOCA = Myocardial Infarction with Non-obstructive Coronary Arteries



Spontaneous coronary dissection








TL: True Lumen FL: False Lumen

Circulation 2019;139:00

Elderly Frail Patient!






Elderly Patients: What is the appropriate use of PCI in ACS and primary PCI in STEMI?



Data from AMIS:

- Increasing use of revascularization by PCI in elderly patients over time
- However, low rate in octogenarians and nonagenarians




Schönenberger A et al. Eur Heart J 2016;37(17):1304-1311

Assessment of Quality of Care in a Comprehensive Way



Clinical Reported Outcome Measures (CROM)

Patient Reported Experience Measures (CREM)
Patient Reported Outcome Measures (CROM)
Costs




Spertus JA et al. Circulation 2003; 107:1681-91

Example of Patient Reported Outcome Measure (PROM)



A. Recurrent angina



B.E. Stähli et al. / International Journal of Cardiology 313 (2020) 16–24

Cost estimates for percutaneous revascularization of ACS in CH



Percutaneous Coronary
Intervention in Switzerland 2020



53'088

coronary angiographies



65%

transradial access



25'933

percutaneous coronary interventions

48.8% of all coronary angiographies



39%


Emergency PCIs



1.36%

overall in-hospital mortality after PCI

0.08% elective | 1.6% in NSTE-ACS | 4.1% in STEMI | 42% in shock



Prize Stent: 500 CHF

On average 2 stents per intervention

2x25933x500= 25,9 Mio/year

Costs DRG:

All PCI: 25'933x13'580= 352,2 Mio CHF

ACS: 39% of 25'933= 10'114 Patients

Costs for invasive treatment of ACS: 137,3 Mio CHF

NB: Costs for lipid lowering therapy in CH 2014: 227Mio CHF*

25 Years of AMIS Plus: What is it worth?



- The AMIS Plus Registry was part and parcel of the successful introduction of a primary PCI in Switzerland.
- AMIS contributed through benchmarking to improvements in process-of-care and quality control in many hospitals.
- Verifies whether RCT results are translatable into routine clinical practice.
- Provides the opportunity to explore the best treatment for ACS of new etiologies and in subgroup of patients.
- Has the potential for expanding quality measure to patient reported outcomes and experience.
- Encourages the use of evidence-based acute cardiac care with the goal of improving patient outcome.